Prosecution Insights
Last updated: April 19, 2026
Application No. 17/777,910

TRPM8 MODULATORS

Non-Final OA §112
Filed
May 18, 2022
Examiner
KENYON, JOHN S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Givaudan SA
OA Round
2 (Non-Final)
80%
Grant Probability
Favorable
2-3
OA Rounds
2y 6m
To Grant
98%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
737 granted / 921 resolved
+20.0% vs TC avg
Strong +18% interview lift
Without
With
+17.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
40 currently pending
Career history
961
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
15.2%
-24.8% vs TC avg
§102
23.6%
-16.4% vs TC avg
§112
38.9%
-1.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 921 resolved cases

Office Action

§112
DETAILED ACTION This action is made second Non-Final to account for new indefiniteness rejections, below, over previously presented claims. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Current Status of 17/777,910 This Office Action is responsive to the amended claims of 5 November 2025 Claims 1, 3-10, and 13-20 have been examined on the merits. Claims 1, 3, 10, and 13-14 are currently amended. Claims 4-9 and 15-20 are previously presented. Priority The effective filing date is 29 November 2019. Response to Arguments The Examiner acknowledges receipt of and has reviewed Applicants’ claim amendments and Reply of 5 November 2025. Applicants revised claim 3 thereby rendering moot the claim objection made within paragraph 13 of the previous Office Action. Applicants revised the claims thereby rendering moot the indefiniteness rejection made within paragraphs 14-16 of the previous Office Action. Applicants revised claim 14 thereby rendering moot the indefiniteness rejection made within paragraph 17 of the previous Office Action. New Rejection Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 6-7 and 17-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 6 recites the limitation "a consumer product". There is insufficient antecedent basis for this limitation in the claim. As drafted, “a consumer product” renders the metes and bounds of claim 6 undefined (hence rendering claim 6 indefinite under 35 USC 112(b)). The artisan has no idea where antecedent basis is to be found since claim 6 is drawn to a composition of matter (claim 6 is a composition of matter statutory category of claim whereas claim 1 is a method statutory category) while claim 1 is drawn to a method. Claim 1 and 6 are drawn to distinct statutory categories of claims. Claims 7 and 17-20 are similarly rejected as indefinite under 35 USC 112(b) for the same rationale. Conclusion Claims 6-7 and 17-20 are rejected under indefiniteness, supra. Claims 1, 3-5, 8-10, and 13-16 are allowable as written for the rationale stated within paragraphs 19-22 of the Non-Final Office Action mailed 22 August 2025. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S KENYON whose telephone number is (571)270-1567. The examiner can normally be reached Monday-Friday 10a-6p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

May 18, 2022
Application Filed
Aug 20, 2025
Non-Final Rejection — §112
Nov 05, 2025
Response Filed
Mar 12, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600713
Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
2y 5m to grant Granted Apr 14, 2026
Patent 12595229
METHOD FOR PRODUCING DERIVATIVE OF ORGANIC SUBSTANCE AND METHOD FOR ANALYZING SAMPLE CONTAINING ORGANIC SUBSTANCE
2y 5m to grant Granted Apr 07, 2026
Patent 12594262
CAI NANOEMULSIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595260
STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12590108
BORACIC ACID COMPOUND
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
80%
Grant Probability
98%
With Interview (+17.8%)
2y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 921 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month